Eurobio Scientific Société anonyme designs, develops, and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient; and commercializes cell culture media, molecular biology reagents, and proprietary antibodies. Its in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; EBX-044 PCR test to enable the identification of SARS-CoV-2 variants; and licensed products comprise AlloMap, a gene-expression profiling based blood test for the surveillance of heart-transplant patients. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
Revenue of Eurobio Scientific Société anonyme (ALERS.PA)
Revenue in 2023 (TTM): $140.66 M
According to Eurobio Scientific Société anonyme's latest financial reports the company's current revenue (TTM) is $140.66 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Eurobio Scientific Société anonyme
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $140.66 M | $57.7 M | $25.2 M | $7.55 M | $5.23 M |
| 2022 | $165.12 M | $70.38 M | $43.88 M | $32.12 M | $26.98 M |
| 2021 | $199.86 M | $105.43 M | $86.4 M | $77.16 M | $65.51 M |
| 2020 | $204.34 M | $114.27 M | $95.46 M | $87.52 M | $79.51 M |
| 2019 | $64.35 M | $19.85 M | $7.51 M | $176.36 K | $3.41 M |
| 2018 | $55.26 M | $19.03 M | $2.43 M | $-3,050,140 | $-2,994,959 |
| 2017 | $46.29 M | $14.02 M | $106.04 K | $-10,038,738 | $-10,786,396 |
| 2016 | $30.11 M | $5.21 M | $-5,360,197 | $-8,928,613 | $-8,367,058 |
| 2015 | $32.22 M | $5.08 M | $-6,566,620 | $-7,005,910 | $-6,361,041 |
| 2014 | $33.59 M | $8.64 M | $-3,636,581 | $-6,992,926 | $-5,936,900 |
| 2013 | $33.78 M | $8.28 M | $-5,041,009 | $-7,715,698 | $-6,485,471 |
| 2012 | $5.83 M | $5.34 M | $-6,904,202 | $-7,263,424 | $-6,243,104 |
| 2011 | $5.4 M | $5.4 M | $-7,929,932 | $-8,874,513 | $-7,681,074 |
| 2010 | $8.84 M | $8.84 M | $-6,780,855 | $-9,821,258 | $-8,383,288 |
| 2009 | $5.29 M | $-4,427,519 | $-9,630,827 | $-10,080,936 | $-8,332,434 |
| 2008 | $4.56 M | $-6,123,003 | $-11,830,520 | $-11,918,161 | $-9,656,794 |
| 2007 | $5.83 M | $-3,488,348 | $-7,853,111 | $-8,672,180 | $-7,941,834 |